Development and evaluation of a prediction model for underestimated invasive breast cancer in women with ductal carcinoma in situ at stereotactic large core needle biopsy.

Assessments of aromatase expression in ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) in 162 cases using semi-quantitative immunohistochemistry found aromatase

We have retrospectively analyzed a series of 155 sequential cases of T1N0M0 ductal carcinomas of which 51 tumors had a ductal carcino- ma in situ (DCIS) component for

Biomolecular evidence has shown that ductal carcinoma in situ (DCIS) may develop into invasive carcinoma of the canine mammary gland, and mutations in proto-oncogenes HER2 and

Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the

Follow-up surgical excision is indicat- ed when breast core needle biopsies show atypical lobular hyperplasia or lobular carcinoma in situ: a correlative study of 33 patients

METHODS: One hundred and twenty-one cases of high-grade ductal carcinoma in situ , pure or associated with invasive mammary carcinoma, were identified from 2003 to 2008 and

The article “Diagnostic underestimation of atypical hyperpla- sia and ductal carcinoma in situ at percutaneous core needle and vacuum-assisted biopsies of the breast in a

Objective: To determine the rates of diagnostic underestimation at stereotactic percutaneous core needle biopsies (CNB) and vacuum- assisted biopsies (VABB) of nonpalpable